FLT3 and acute myeloid leukemia: Another study evaluating crenolanib in the refractory/relapsed AML with FLT3-ITD setting found that crenolanib resulted in a 39% CRi and 11% partial response (PR) in those patients who had not received FLT3 inhibition previously, with an OS of 234 days [37].